Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]BU99008 is a radiolabeled positron emission tomography (PET) ligand specifically developed for imaging imidazoline2 binding sites (I2BS) in the brain. I2BS are believed to be expressed predominantly in glial cells and are implicated in the regulation of glial fibrillary acidic protein, with potential roles in neurodegenerative and neuroinflammatory diseases. [11C]BU99008 demonstrates high affinity and selectivity for I2BS, with minimal off-target binding to monoamine oxidase (MAO). It exhibits good brain penetration, reversible kinetics, heterogeneous distribution consistent with known I2BS expression patterns, and reliable test-retest reproducibility. The compound is used as a diagnostic radiopharmaceutical tool for research purposes to investigate alterations of I2BS expression in various neurological conditions[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]BU99008.